Tumor-agnostic therapies for cancer patients with biomarkers RET fusion, HER2, FGFR mutations, KRAS mutations, ROS1, ALK, G12C, neuregulin 1 (NRG1) fusion [210,212,214], PD-L1 overexpression, and APOBEC alteration [212] are under consideration. This evidence concerns the gene ERBB2 and neoplasm.